Zentalis Pharmaceuticals has dosed the first patient in the Phase 3 ASPENOVA trial, testing azenosertib for Cyclin E1-positive platinum-resistant ovarian cancer. This trial compares azenosertib to standard chemotherapy and aims to confirm benefits seen in earlier Phase 2 studies, supporting full FDA approval. The ASPENOVA study enrolls about 420 patients globally and focuses on progression-free survival as the primary endpoint. Results from the ongoing Phase 2 DENALI trial, expected by the end of 2026, may lead to accelerated approval, while ASPENOVA will provide confirmatory data for full approval.
The Dolphin Company's current management proposed selling its main assets in Mexico to Delphinus Blue Planet, a Grupo Xcaret subsidiary, for $20 million. This deal would give Delphinus control over more than 90% of dolphin habitats in Mexico, creatin...
Johnson & Johnson has reached a historic $5.5 billion settlement to resolve claims from about 70,000 women and families alleging its talc products, including Johnson's Baby Powder, contained asbestos and caused cancers such as ovarian cancer and meso...
Catalyst Acquisition Corp. announced the pricing of its initial public offering (IPO) at $10 per unit, raising $200 million by offering 20 million units. The units, each including one Class A ordinary share and a partial share right, will begin tradi...
On July 27, Bitcoin ETFs experienced an outflow of $11.6 million, indicating a possible short-term drop in investor demand. Meanwhile, Ethereum funds saw an inflow of $9.2 million, reflecting growing positive sentiment toward Ethereum. These contrast...
Indonesian equities have entered bull-market territory after a significant rebound from a five-year low in early June, driven by attractive valuations and regulatory measures. MSCI's decision to delay downgrading Indonesia's market status from emergi...
